These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

89 related articles for article (PubMed ID: 7636736)

  • 1. Ritanserin, a 5-HT2A/2C antagonist, reverses direct dopamine agonist-induced inhibition of midbrain dopamine neurons.
    Shi WX; Nathaniel P; Bunney BS
    J Pharmacol Exp Ther; 1995 Aug; 274(2):735-40. PubMed ID: 7636736
    [TBL] [Abstract][Full Text] [Related]  

  • 2. D1 dopamine receptor stimulation enables the postsynaptic, but not autoreceptor, effects of D2 dopamine agonists in nigrostriatal and mesoaccumbens dopamine systems.
    Wachtel SR; Hu XT; Galloway MP; White FJ
    Synapse; 1989; 4(4):327-46. PubMed ID: 2532422
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Chloral hydrate anesthesia alters the responsiveness of identified midbrain dopamine neurons to dopamine agonist administration.
    Kelland MD; Freeman AS; Chiodo LA
    Synapse; 1989; 3(1):30-7. PubMed ID: 2919369
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ritanserin, a 5-HT2 receptor antagonist, activates midbrain dopamine neurons by blocking serotonergic inhibition.
    Ugedo L; Grenhoff J; Svensson TH
    Psychopharmacology (Berl); 1989; 98(1):45-50. PubMed ID: 2524859
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dopamine agonists at repeated "autoreceptor-selective" doses: effects upon the sensitivity of A10 dopamine autoreceptors.
    Jeziorski M; White FJ
    Synapse; 1989; 4(4):267-80. PubMed ID: 2603146
    [TBL] [Abstract][Full Text] [Related]  

  • 6. D1-D2 interaction in feedback control of midbrain dopamine neurons.
    Shi WX; Smith PL; Pun CL; Millet B; Bunney BS
    J Neurosci; 1997 Oct; 17(20):7988-94. PubMed ID: 9315916
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ontogeny of nigrostriatal dopamine neuron autoreceptors: iontophoretic studies.
    Wang L; Pitts DK
    J Pharmacol Exp Ther; 1995 Jan; 272(1):164-76. PubMed ID: 7815330
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of L-DOPA on nigral dopamine neurons and local field potential: comparison with apomorphine and muscimol.
    Xu D; Karain B; Brantley E; Shi WX
    J Pharmacol Exp Ther; 2011 May; 337(2):533-9. PubMed ID: 21330359
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of (+)-4-propyl-9-hydroxynaphthoxazine on midbrain dopamine neurons: an electrophysiological study.
    Kelland MD; Freeman AS; LeWitt PA; Chiodo LA
    J Pharmacol Exp Ther; 1990 Oct; 255(1):276-84. PubMed ID: 1976800
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Repeated D1 dopamine receptor agonist administration prevents the development of both D1 and D2 striatal receptor supersensitivity following denervation.
    Hu XT; White FJ
    Synapse; 1992 Mar; 10(3):206-16. PubMed ID: 1532677
    [TBL] [Abstract][Full Text] [Related]  

  • 11. SKF 38393 alters the rate-dependent D2-mediated inhibition of nigrostriatal but not mesoaccumbens dopamine neurons.
    Kelland MD; Freeman AS; Chiodo LA
    Synapse; 1988; 2(4):416-23. PubMed ID: 2973142
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Repeated stimulation of dopamine D2-like receptors: reduced responsiveness of nigrostriatal and mesoaccumbens dopamine neurons to quinpirole.
    Pitts DK; Wang L; Kelland MD; Freeman AS; Chiodo LA
    J Pharmacol Exp Ther; 1995 Oct; 275(1):412-21. PubMed ID: 7562579
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Repeated amphetamine administration: role of forebrain in reduced responsiveness of nigrostriatal dopamine neurons to dopamine agonists.
    Pitts DK; Kelland MD; Freeman AS; Chiodo LA
    J Pharmacol Exp Ther; 1993 Feb; 264(2):616-21. PubMed ID: 8094749
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Loss of D1/D2 dopamine receptor synergisms following repeated administration of D1 or D2 receptor selective antagonists: electrophysiological and behavioral studies.
    Hu XT; White FJ
    Synapse; 1994 May; 17(1):43-61. PubMed ID: 7913772
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Serotonergic afferent regulation of the basic physiology and pharmacological responsiveness of nigrostriatal dopamine neurons.
    Kelland MD; Freeman AS; Chiodo LA
    J Pharmacol Exp Ther; 1990 May; 253(2):803-11. PubMed ID: 1971022
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Neurotensin attenuates dopamine D2 agonist quinpirole-induced inhibition of midbrain dopamine neurons.
    Shi WS; Bunney BS
    Neuropharmacology; 1990 Nov; 29(11):1095-7. PubMed ID: 1982340
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CI-1007, a dopamine partial agonist and potential antipsychotic agent. I. Neurochemical effects.
    Rugsley TA; Davis MD; Akunne HC; Cooke LW; Whetzel SZ; MacKenzie RG; Shih YH; van Leeuwen DH; DeMattos SB; Georgic LM
    J Pharmacol Exp Ther; 1995 Aug; 274(2):898-911. PubMed ID: 7636753
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Differential agonist profile of the enantiomers of 3-PPP at striatal dopamine autoreceptors: dependence on extracellular dopamine.
    Clark D; Salah RS; Galloway MP
    Synapse; 1991 Jul; 8(3):169-76. PubMed ID: 1948667
    [TBL] [Abstract][Full Text] [Related]  

  • 19. 5-HT2 receptors differentially modulate dopamine-mediated auto-inhibition in A9 and A10 midbrain areas of the rat.
    Olijslagers JE; Werkman TR; McCreary AC; Siarey R; Kruse CG; Wadman WJ
    Neuropharmacology; 2004 Mar; 46(4):504-10. PubMed ID: 14975674
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In vivo comparisons of the effects of quinpirole and the putative presynaptic dopaminergic agonists B-HT 920 and SND 919 on striatal dopamine and acetylcholine release.
    Robertson GS; Tham CS; Wilson C; Jakubovic A; Fibiger HC
    J Pharmacol Exp Ther; 1993 Mar; 264(3):1344-51. PubMed ID: 8095550
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.